Loading...
Loading...
RGEN| Name | Value |
|---|---|
| Revenues | 186.8M |
| Cost of Revenue | 90.7M |
| Gross Profit | 96.1M |
| Operating Expense | 64.3M |
| Operating I/L | 17.7M |
| Other Income/Expense | 35.3M |
| Interest Income | 0.0M |
| Pretax | 53.0M |
| Income Tax Expense | 4.3M |
| Net Income/Loss | 48.7M |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for biological drug manufacturing. Its products include Protein A ligands, chromatography columns, ELISA test kits, filtration devices, and process analytics systems. These are used in the purification of biologics, high throughput process development, viral clearance validation, and biologic drug concentration and formulation processes. The company's customers include life sciences, biopharmaceutical, and diagnostics companies, laboratory researchers, and contract manufacturing organizations.
